Mark G Foletta
CIK 1236389 · EVP & Chief Financial Officer · last filed 2026-08-04
Mark G Foletta is an EVP & Chief Financial Officer who has filed 130 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider sold $330.6K of DXCM on Aug 4, 2026. Across all open-market trades the lifetime net is −$8.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DXCM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 500
DALLAS, TX 75019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DXCM | Director | 57,183 | $79.92 | $4.57M | -$5.96M | 39 | 2026-08-04 |
| AMN | Director | 41,515 | $37.81 | $1.57M | -$1.20M | 21 | 2026-06-17 |
| ENTA | Director | — | $11.22 | — | $0 | 7 | 2026-03-13 |
| Forte Biosciences, Inc. (TOCA) Delisted | EVP & Chief Financial Officer | 1,003 | — | — | $71.5K | 7 | 2019-10-04 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 683 | $8.16 | $5.6K | $76.4K | 7 | 2017-12-06 |
| AMN HEALTHCARE SERVICES INC (AHS) Delisted | Director | 5,532 | — | — | $0 | 4 | 2016-04-22 |
| BIOCEPT INC (BIOC) Delisted | Interim CFO | — | $0.43 | — | $0 | 1 | 2015-09-02 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 2 | 2014-11-12 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | SVP, Chief Financial Officer | 81,344 | — | — | -$1.48M | 25 | 2012-07-26 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | — | — | — | $0 | 6 | 2011-05-27 |
Recent Filings
130 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-04 | DXCM | Sell (S) | −4,000 | -$330.6K | EDGAR |
| 2026-08-03 | DXCM | Notice (144) | −2,000 | -$170.6K | EDGAR |
| 2026-07-31 | DXCM | Notice (144) | −2,000 | -$160.0K | EDGAR |
| 2026-06-17 | AMN | Sell (S) | −3,681 | -$114.4K | EDGAR |
| 2026-06-17 | DXCM | Sell (S) | −4,000 | -$296.5K | EDGAR |
| 2026-06-15 | DXCM | Notice (144) | −4,000 | -$302.8K | EDGAR |
| 2026-06-15 | AMN | Notice (144) | −3,681 | -$114.1K | EDGAR |
| 2026-06-01 | DXCM | Grant (A) | +6,331 | $0 | EDGAR |
| 2026-05-11 | DXCM | Gift (G) | — | $0 | EDGAR |
| 2026-05-04 | AMN | Mixed | +8,325 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.